Cryoport is a global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport’s clients include Novartis, Gilead and bluebird bio which use Cyroport’s services for their current and under development CAR-T products. Cryoport’s solutions are used by points-of-care, CROs, central laboratories, pharmaceutical companies, manufacturers, university researchers, and more; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary portfolio includes Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology.
McKesson Specialty Health is a division of McKesson Corporation that works together with stakeholders across the healthcare delivery system to preserve and strengthen specialty care. By providing innovative provider, practice management, biopharma and payer solutions, McKesson Specialty Health works towards improving the financial, operational and business health of their customers and partners so they may provide the best care to patients. By collaborating with Cryoport they will gain cold-chain logistics solutions for temperature-sensitive biologic materials, such as immunotherapies, stem cells, CAR-T cells, biologics and reproductive cells.
Biobanks are suppliers of stem cells, reproductive cells, and the raw materials for basic research, which store materials close to -180ºC (liquid nitrogen), so when it comes to distribution of live (frozen) cellular products, logistics providers with experience in ultra-low temperature handling are required. Cryoport and McKesson Specialty Health can potentially help link biobanks to sites where the material need is greatest in the most regulatory compliant manner possible. To remain regulatory compliant companies dealing with biologic materials are obliged to make use of technologies such as temperature monitors during shipping and need contingency plans for temperature deviations beyond acceptable levels. Over 25% of regenerative medicines’ product cost can be accounted for in shipping and distribution.
Sources
- https://www.businesswire.com/news/home/20180226005239/en
- http://www.bioprocessintl.com/manufacturing/cell-therapies/manufacturing-cell-therapies-commercial-scale-efficiency/
